Poxel Appoints Janice Bourque and Pierre Legault to its Board of Directors
POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced the addition of Janice Bourque, Managing Director of Hercules Technology Growth Capital, and Pierre Legault, President and CEO of Nephrogenex Inc, to its Board of Directors. Both appointments were approved by Poxel’s shareholders at the Annual Shareholder Meeting held in Paris last Friday, January 29, 2016.
...Pierre studied International Finance, Business & Commerce and earned an MBA in Marketing from McGill University in Montreal, Canada. Additionally, he completed the Executive Masters Program for InfoTechnology & Services at Havard Business School and he is a CPA.
Read full article: City Biz List, 1 February, 2016
Feedback
For more information or if you would like to report an error, please web.desautels [at] mcgill.ca (subject: Website%20News%20Comments) (contact us).
